What Meriofert 150 IU Treats: Main Uses and Benefits

The primary therapeutic domain of Meriofert 150 IU is the management of specific types of female infertility. The medication is applied across two main therapeutic domains generally relevant for women. The core conditions it helps manage include the lack of natural ovulation (anovulation) and its use as a supportive element during Assisted Reproductive Technology (ART) cycles.

Supporting Ovulation and Stability During Symptomatic Episodes

This medication is applied in clinical settings that involve episodic or fluctuating symptom patterns associated with symptoms related to systemic imbalance. Meriofert provides supportive relief that is commonly used to help with conditions where functional stability becomes affected when a patient has not responded to previous management options. It assists with maintaining functional stability and eases distress during difficult episodes.

Assisting in Specific Clinical Scenarios

In scenarios such as ART, Meriofert is used when symptoms may intensify temporarily or when there is a heightened systemic burden in situations requiring additional symptomatic assistance. This use contributes to easing the overall symptom burden for patients undergoing complex procedures and supports general well-being during symptomatic phases.

---

Quick Fact: Focus on Symptoms related to Systemic Imbalance

Meriofert 150 IU is approved exclusively for adult women seeking treatment for specific types of anovulatory infertility or those undergoing Controlled Ovarian Hyperstimulation (COH) for Assisted Reproductive Technology (ART) procedures. Regulatory guidelines strictly define populations who must not use the medicine, primarily revolving around safety risks and the presence of pre-existing conditions that render treatment inappropriate or hazardous.

Contraindications (Must Not Use)

Use of Meriofert 150 IU is absolutely contraindicated in patients with a known hypersensitivity to menotrophin, as well as in women diagnosed with primary ovarian failure (indicated by high FSH levels). It is prohibited for individuals with sex hormone-dependent tumours (e.g., ovarian, uterine, or breast carcinoma) or tumours of the hypothalamus or pituitary gland. Women with gynaecological bleeding of unknown cause must not use this medicine.

Eligibility Restrictions

The medication is contraindicated during pregnancy and lactation. Furthermore, Meriofert is not intended for use by children or adolescents, nor is it used in the geriatric population. Women with anatomical barriers, such as malformations of the sexual organs or fibroid tumours of the uterus incompatible with pregnancy, are also ineligible. Use is restricted in women with risk factors for thromboembolic events, and safety and efficacy have not been established for women with renal or hepatic insufficiency.

Interactions with Other Medicines and Products

Official regulatory documents detail specific drug-drug interactions for Meriofert 150 IU based on expected effects on treatment response, rather than solely on changes in drug concentration. No formal human interaction studies have been conducted; however, potential effects when combined with certain therapeutic agents are documented to guide professional use.

Documented Interacting Substances and Effects

Interacting Product Category	Expected Interaction Effect	Constraint or Requirement
Clomiphene Citrate	Expected to enhance the follicular response.	Combination use requires professional monitoring due to augmented effect.
GnRH Agonists	May necessitate a higher quantity of Meriofert.	Combination use requires dose adjustment to achieve an adequate therapeutic response.

Regulatory Notes on Interactions

Regulatory assessments classify these as interactions that require professional management and potential dose modification. The official profile does not list any absolute 'do-not-combine' restrictions (contraindications) within the interaction section itself, but highlights necessary professional adjustments.

There are no explicit regulatory statements concerning interactions with food, alcohol, or herbal products. The documented constraints are centered on the combined physiological effects with other fertility-related medicines. This structure ensures that potential additive or response-modifying effects are addressed during treatment planning.

How Meriofert 150 IU Works

Targeted Hormone Receptor Activation

Meriofert 150 IU contains active components that function as agonists, directly binding to and activating the specific Follicle-Stimulating Hormone receptors (FSHR) and Luteinizing Hormone receptors (LHR) located on cells within the ovary. This interaction initiates the necessary intracellular signaling cascades, which are crucial for cellular growth and differentiation, providing the hormonal signal required for follicular progression.

Driving Follicular Growth and Development

The drug specifically modulates the folliculogenesis cascade by supplying the key FSH signal, which is required for the continued growth and differentiation of ovarian follicles past their initial stage. This targeted pathway modulation stimulates the proliferation of granulosa cells and promotes the activity of key enzymes, leading to the advancement toward maturity of multiple ovarian follicles.

Enhancing Ovarian Steroid Synthesis

In addition to growth, the LH activity (including Human Chorionic Gonadotropin) enhances the steroidogenesis pathway within the maturing follicles. This interaction increases the cellular production of steroid hormones, such as estrogen, which are important physiological modulators. The resulting elevated hormone output from the follicles contributes to the necessary maturation of the ovarian structure and influences the systemic hormonal environment that mediates the subsequent phase of the cycle.

How to use Meriofert 150 IU — Official Administration Guidelines

Meriofert 150 IU is a powder and solvent for solution for injection. It is administered daily via subcutaneous (under the skin) or intramuscular injection, as prescribed and trained by a healthcare professional. The dosage is always individualized and adjusted by a physician based on clinical and laboratory monitoring of ovarian response.

---

Dosing and Timing

Administration Detail	Official Guideline
Route of Administration	Subcutaneous or Intramuscular injection.
Frequency	Daily injection.
Typical Starting Dose (ART)	150–300 IU (1–2 vials) daily, starting on the 2nd or 3rd day of the cycle.
Cycle Duration	Continued daily until adequate follicular development is reached, as determined by the physician.
Missed Dose	Consult your doctor immediately if a dose is missed.

---

Preparation and Procedure

Meriofert powder must be reconstituted immediately before use, and the injection should be administered as soon as the solution is prepared. The reconstitution process must be carried out under aseptic conditions on a clean surface with thoroughly washed hands.

1. Reconstitution: Draw up the solvent provided into a syringe using the large reconstitution needle. Inject the solvent into the vial containing the Meriofert powder. Up to three vials of powder may be dissolved in one milliliter (1 ml) of the solvent provided to avoid large injection volumes.
2. Mixing: Do not shake the vial. Instead, gently roll it between the hands until the powder is completely dissolved. The resulting solution must be clear and contain no particles before use.
3. Injection: Change to the finer, smaller injection needle. The subcutaneous injection is typically given in the lower and lateral parts of the abdomen.
4. Technique: Clean the injection area with an alcohol swab. Pinch the skin to form a fold, insert the needle completely, and gently push the plunger in a slow, steady movement until all the solution is injected. The injection site should be changed daily.

---

Research evidence / Overview of studies for Meriofert 150 IU

---

Evidence for use in Controlled Ovarian Stimulation (ART)

This section will summarize the structure of large Randomized Controlled Trials (RCTs) and comparative studies that examined the use of Menotropins in relation to multiple egg development for procedures like IVF and ICSI. The focus will be on the clinical and biological outcomes, such as pregnancy and oocyte metrics, measured in these key clinical trials.

Research exploring the use of Menotropins for Assisted Reproductive Technology (ART) primarily involved large, multi-center RCTs. These studies often evaluated Menotropins against other gonadotropin medications, such as recombinant Follicle Stimulating Hormone (rFSH). The researchers measured clinical endpoints like the Ongoing Pregnancy Rate (OPR), typically confirmed by a fetal heartbeat, and the Live Birth Rate (LBR). Studies reported various metrics allowing for the calculation of cumulative pregnancy rates. Findings describe patterns observed in the measured pregnancy and birth rates across the study groups. What remains uncertain is that many studies were designed to evaluate if Menotropins performed similarly to (non-inferior to) an approved comparator. Long-term outcomes over many years are not fully established in the research.

---

Evidence for use in Ovulation Induction (Anovulation)

This part will outline the research designs, including randomized and controlled trials, that have investigated Menotropins use in women with ovulatory dysfunction who have not responded to previous oral fertility medications. It will describe the clinical and physiological endpoints used by researchers to evaluate the follicular response and confirmation of ovulation.

Research examined Menotropins in the context of ovulation induction in women who have difficulty ovulating naturally. The research involved comparative clinical trials that tracked outcomes related to this use, particularly in women with conditions like Polycystic Ovarian Disease (PCOD) who had not conceived with prior oral agents. Researchers monitored clinical endpoints that included the rate of confirmed ovulation and the resulting Clinical Pregnancy Rate (CPR). Evidence is largely focused on women who were unresponsive to prior oral medications, limiting the insight into its use in the general anovulatory population. Additionally, a portion of the evidence base relies on established, older trials, and findings were mixed regarding specific comparisons.

---

Long-term studies and follow-up

The clinical research for Menotropins generally features follow-up durations that were limited to the time required to confirm early pregnancy or the subsequent live birth. While some studies tracked cumulative live birth rates, this follow-up rarely extends beyond six months or a year after the initial treatment cycle. Research has explored outcomes related to the health of offspring resulting from ART cycles where Menotropins was used. However, long-term effects on the mother beyond the immediate treatment phase are not fully established or consistently characterized across the research base.

---

What is still uncertain about Menotropins Research

Regulatory reviews and research analyses highlight several areas where certainty remains low or evidence is limited. A key limitation is that long-term effects are not fully established because follow-up durations were typically short in the largest trials. Furthermore, the research findings relate primarily to the populations studied—adult women undergoing standard fertility procedures under specific inclusion criteria—and do not provide sufficient insight into the use of Menotropins in women with certain underlying health issues.

Common questions about Meriofert 150 IU (FAQ)

---

Q: Why is Meriofert described as highly purified?

A: Meriofert is officially described as a highly purified human menopausal gonadotrophin (hMG). This emphasis on purity relates to its manufacturing process, which uses standardized methods to ensure the removal of impurities, distinguishing it from older, less purified urinary-derived hormone preparations.

---

Q: What fertility problems is Meriofert typically used for?

A: Meriofert is used to promote ovarian function in adult women dealing with specific infertility challenges. Official information indicates its use for anovulatory infertility (when the patient is not ovulating) and as part of Assisted Reproductive Technology (ART) procedures, such as In Vitro Fertilization (IVF).

---

Q: Does Meriofert 150 IU cause weight gain?

A: Regulatory documents do not list weight gain as a common or very common adverse reaction on its own. However, a sign of the serious condition Ovarian Hyperstimulation Syndrome (OHSS), which is a documented safety risk, is rapid weight gain.

---

Q: Can Meriofert 150 IU be used by women who have PCOS?

A: Clinical research has included women with ovulatory dysfunction, specifically those with conditions like Polycystic Ovarian Disease (PCOD). The official safety profile suggests that its use is considered in the context of this condition, as it lists ovarian cysts not due to polycystic ovary syndrome as a contraindication (a reason to not use the medicine).

---

Q: Is Meriofert 150 IU available as a pen or only as a vial/ampoule?

A: The official administration instructions for Meriofert 150 IU describe it as a powder and solvent supplied in vials and ampoules. This format requires reconstitution using a syringe and needle before use, and is distinct from pre-filled pen devices.

---

Q: Is there a difference in effectiveness between Meriofert 150 IU and other FSH/LH containing products?

A: Research has often compared menotropins (Meriofert’s active component) against other hormone medications, such as recombinant FSH. Research themes often focus on non-inferiority, where different preparations are observed to have similar clinical and biological outcomes.

---

Q: Does the time of day matter when using Meriofert 150 IU?

A: Official guidelines specify that Meriofert must be used as a daily injection. Although regulatory information does not specify a precise time of day, a consistent daily schedule is important for maintaining accurate clinical and laboratory monitoring, which guides the prescribing physician's decisions.

---

Q: Can Meriofert 150 IU affect mood or cause emotional changes?

A: The official adverse reaction lists include central nervous system effects like headache and dizziness in the common or uncommon categories. However, reports of mood changes or significant emotional effects are not listed among the most frequent side effects in the official safety documentation.

---

Q: Is it unsafe to drink caffeine while undergoing treatment with Meriofert 150 IU?

A: The official regulatory documents detailing product interactions do not contain explicit statements or warnings regarding specific interactions with food, drink, or general consumption items like caffeine during treatment with Meriofert 150 IU.

---

Q: Is Meriofert 150 IU suitable for women over the age of 40?

A: Meriofert 150 IU is approved for use in adult women undergoing fertility treatment. Clinical study protocols for the medication have included women over the age of 35, where the starting dosage is often subject to adjustment based on factors including the patient’s age.

---

Q: Are there different strengths of Meriofert other than 150 IU?

A: Yes, formulations containing the active ingredient menotropins are generally available in different strengths. Meriofert is also available as a formulation containing 75 International Units (IU) of human Follicle Stimulating Hormone (FSH) activity and 75 IU of human Luteinising Hormone (LH) activity.

---

Q: Does Meriofert 150 IU interact with common medications for thyroid issues?

A: Specific interactions with individual thyroid medications are not detailed in the interactions section. However, the official profile notes that Meriofert is contraindicated (must not be used) in women who exhibit uncontrolled non-gonadal endocrinopathies, which include severe thyroid conditions.

---

Q: Do studies suggest any specific genetic factors influence response to Meriofert?

A: The summary of clinical research generally focuses on clinical outcomes and does not detail specific genetic factors influencing drug response. However, regulatory summaries mention that differences in parental genetic background are among the characteristics that may be related to certain outcomes observed in assisted reproductive technology (ART) cycles.

---

Q: Can Meriofert 150 IU cause symptoms similar to those of menopause?

A: Some side effects reported in the official safety profile, such as hot flush and certain breast complaints (including tenderness and swelling), are also recognized as symptoms that may occur during menopause.

---

Q: Does Meriofert 150 IU require a prescription from a specialist?

A: Official labeling states that Meriofert 150 IU must be used under the supervision of a doctor (physician). Furthermore, the product is intended to be prescribed and managed by clinicians who are experienced in the treatment of infertility.

Storage and Disposal of Meriofert 150 IU

Official Storage Conditions

The Meriofert 150 IU powder and solvent must be stored at a temperature not above 25 C. To maintain product integrity, the vials and ampoules must be kept in the outer carton for protection from light. It is mandatory to keep the medicinal product out of the sight and reach of children.

Stability and Waste

After the powder is mixed with the solvent (reconstitution), the solution must be used immediately. The official labeling requires that any remaining reconstituted solution or unused product be discarded.

Disposal Instructions

Do not dispose of this medicine via wastewater or household waste. Unused product and waste materials must be disposed of in accordance with local requirements to protect the environment and comply with regulatory protocols for pharmaceutical waste.